These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice. Parnetti L; Lanari A; Saggese E; Spaccatini C; Gallai V Neurol Sci; 2003 Oct; 24(3):199-200. PubMed ID: 14598086 [TBL] [Abstract][Full Text] [Related]
23. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606 [TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699 [TBL] [Abstract][Full Text] [Related]
25. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209 [TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286 [TBL] [Abstract][Full Text] [Related]
36. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Herukka SK; Hallikainen M; Soininen H; Pirttilä T Neurology; 2005 Apr; 64(7):1294-7. PubMed ID: 15824371 [TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia. Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055 [TBL] [Abstract][Full Text] [Related]
38. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Lewczuk P; Esselmann H; Otto M; Maler JM; Henkel AW; Henkel MK; Eikenberg O; Antz C; Krause WR; Reulbach U; Kornhuber J; Wiltfang J Neurobiol Aging; 2004 Mar; 25(3):273-81. PubMed ID: 15123331 [TBL] [Abstract][Full Text] [Related]
39. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456 [TBL] [Abstract][Full Text] [Related]
40. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]